European commission approves forxiga (dapagliflozin) for the treatment of symptomatic chronic heart failure with reduced ejection fraction in adults. PRESS RELEASE Dapagliflozin is the first SGLT2 inhibitor approved in the […]
1.The content in this website should not replace and/or substitute the interactions with and advice you get from your healthcare professional, and if you have any concerns about your condition you should discuss these with your healthcare professional at the earliest opportunity.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.